A combination of an anti-CD19 maytansinoid immunoconjugate and rituximab is used for treating CD19+CD20+ B-cell malignancies symptom, in particular Non-Hodgkin's lymphoma.
COMBINATION THERAPY FOR THE TREATMENT OF CD19+ B-CELL MALIGNANCIES SYMPTOMS COMPRISING AN ANTI-CD1 MAYTANSINOID IMMUNOCONJUGATE AND RITUZIMAB